---
title: "Dermata Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286309961.md"
datetime: "2026-05-13T20:10:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286309961.md)
  - [en](https://longbridge.com/en/news/286309961.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286309961.md)
---

# Dermata Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.48.

EBIT: As of FY2026 Q1, the actual value is USD -2.005 M.

Dermata Therapeutics, Inc. reported its financial results for the first quarter of 2026. The company’s cash and cash equivalents decreased from $7.5 million as of December 31, 2025, to $6.9 million as of March 31, 2026, a $0.6 million decrease during the quarter. This decrease was influenced by $2.0 million in net proceeds from its at-the-market (ATM) financing facility, offset by approximately $0.1 million in equity financing-related expenses and $2.5 million of cash used in operations.

#### Operating Expenses

Research and Development (R&D) expenses for the quarter ended March 31, 2026, were $0.4 million, a decrease from $1.3 million for the same period in 2025. This $0.9 million decrease was primarily due to $0.7 million in decreased clinical expenses, $0.1 million in decreased chemistry, manufacturing and controls (CMC) and non-clinical expenses, and $0.1 million in decreased personnel expenses. Selling, General and Administrative (SG&A) expenses increased to $1.5 million for the quarter ended March 31, 2026, compared to $1.1 million for the same period in 2025, mainly due to $0.2 million in marketing expenses, $0.2 million in increased audit fees, and $0.1 million in increased legal fees. Total operating expenses for the quarter ended March 31, 2026, were $1.9 million, a decrease from $2.3 million for the quarter ended March 31, 2025.

#### Loss from Operations

Loss from operations was - $1.9 million for the first quarter of 2026, an improvement from - $2.3 million for the first quarter of 2025.

#### Interest Income

Interest income increased to $79 thousand for the quarter ended March 31, 2026, from $36 thousand for the same period in 2025.

#### Net Loss

Dermata Therapeutics, Inc. reported a net loss of - $1.8 million for the first quarter of 2026, compared to a net loss of - $2.3 million for the first quarter of 2025.

#### Stock-Based Compensation Expense

Stock-based compensation expense included $14 thousand for Research and Development and $29 thousand for Selling, General and Administrative expenses in Q1 2026, compared to $8 thousand for Research and Development and $29 thousand for Selling, General and Administrative expenses in Q1 2025.

#### Balance Sheet Highlights (as of March 31, 2026, in thousands USD)

Total Assets were $7,465, down from $7,864 as of December 31, 2025. Inventory was $93, up from - as of December 31, 2025. Total Liabilities were $1,052, down from $1,641 as of December 31, 2025. Equity was $6,413, up from $6,223 as of December 31, 2025.

#### Operational Metrics and Corporate Highlights

Dermata Therapeutics, Inc. announced its new direct-to-consumer (DTC) skincare brand, Tome, in March 2026. The company hired Kyra Peckaitis as Vice President of Marketing in March 2026 to lead the Tome skincare brand.

#### Outlook / Guidance

Dermata Therapeutics, Inc. plans to launch its first DTC product, the Tome Foundational Treatment, in the middle of 2026, and is preparing for the launch of a second DTC product to follow. The company expects its current cash resources to be sufficient to fund operations into the first quarter of 2027.

### Related Stocks

- [DRMA.US](https://longbridge.com/en/quote/DRMA.US.md)

## Related News & Research

- [Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4](https://longbridge.com/en/news/286958909.md)
- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [ACG METALS LIMITED:Approval of DTC Eligibility to Improve U.S. Trading Liquidity | ACGAF Stock News](https://longbridge.com/en/news/286367000.md)
- [Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference | DERM Stock News](https://longbridge.com/en/news/286965311.md)